flosz schreef op 7 oktober 2014 14:37:
Betaling in 1 keer, behandeling in termijnen(.......one-time administration of glybera)
www.ema.europa.eu/docs/en_GB/document...Zie pagina 3.
Uit 2012:
Jörn Aldag, UniQure’s chief executive, said he would probably charge €250,000 a year for five years for the drug, a similar amount to Cerezyme, another “orphan drug” for a very rare disease. That would indicate a total bill of €1.25m per patient.
He said the company planned an innovative approach to pricing, using an “annuity stream” so that hospitals would be charged a proportion of the total price each year for five years. Glybera is given through a single series of injections in the upper leg muscle over three hours.
He stressed that the price was necessary in order to cover development costs and because use would be limited to potentially just a few hundred patients across Europe, who currently cost the health system large sums because of emergency hospital admissions to deal with pancreatitis and other complications of the disease.
www.iex.nl/Forum/Topic/1286507/2/Morg...